Obatoclax

Drug Profile

Obatoclax

Alternative Names: CEP-41601; GX 15-070; GX15-070MS; Obatoclax mesylate

Latest Information Update: 07 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gemin X Biotechnologies
  • Class Antineoplastics; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Autophagy stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Chronic lymphocytic leukaemia; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Aplastic anaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Small cell lung cancer; Systemic mastocytosis

Most Recent Events

  • 31 Dec 2013 Discontinued - Phase-I for Multiple myeloma in USA (IV)
  • 31 Dec 2013 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia in USA and Canada (IV)
  • 31 Dec 2013 Discontinued - Phase-I/II for Mantle cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top